Carregant...

A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: near final height analysis

BACKGROUND—Turner syndrome accounts for 15-20% of childhood usage of growth hormone (GH) in the UK but final height benefit remains uncertain. The most effective strategy for oestrogen replacement is also unclear.
METHODS—Fifty eight girls who, at start of treatment, were of mean age 9.1 years and p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Johnston, D, Betts, P, Dunger, D, Barnes, N, Swift, P, Buckler, J, Butler, G
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2001
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1718629/
https://ncbi.nlm.nih.gov/pubmed/11124794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/adc.84.1.76
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!